KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer

被引：0

作者：

Shitara, K. ^{[1
]}

Ozguroglu, M. ^{[2
]}

Bang, Y. J. ^{[3
]}

Di Bartolomeo, M. ^{[4
]}

Mandala, M. ^{[5
]}

Ryu, M. H. ^{[6
]}

Fornaro, L. ^{[7
]}

Olesinski, T. ^{[8
]}

Caglevic, C. ^{[9
]}

Chung, H. ^{[10
]}

Muro, K. ^{[11
]}

Gokkurt, E. ^{[12
]}

Mansoor, W. ^{[13
]}

McDermott, R. ^{[14
]}

Schacham-Shmueli, E. ^{[15
]}

Chen, X. ^{[16
]}

Kang, S. P. ^{[16
]}

Mayo, C. ^{[16
]}

Ohtsu, A. ^{[1
]}

Fuchs, C. ^{[17
]}

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[3] Seoul Natl Univ, Coll Med, Seoul, South Korea

[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[5] Papa Giovanni XXIII Hosp, Bergamo, Italy

[6] Asan Med Ctr, Seoul, South Korea

[7] Azienda Osped Univ Pisana, Pisa, Italy

[8] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[9] Inst Oncol Fdn Arturo Lopez Perez, Santiago, Chile

[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[12] HOPE, Hamburg, Germany

[13] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[14] Adelaide & Meath Hosp, Dublin, Ireland

[15] Sheba Med Ctr, Ramat Gan, Israel

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Yale Canc Ctr, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA - 005

引用

页数：1

共 50 条

[41] Phase I study to evaluate the safety, tolerability and preliminary efficacy of rivoceranib plus paclitaxel in advanced gastric or gastroesophageal junction (GEJ) cancer
Ryu, M. H.
Pande, A.
Kim, J. H.
Kang, Y-K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1114 - S1114
[42] A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
Boku, N.
Kang, Y-K.
Satoh, T.
Chao, Y.
Kato, K.
Chung, H. C.
Chen, J-S.
Muro, K.
Kang, W. K.
Yoshikawa, T.
Oh, S. C.
Tamura, T.
Lee, K-W.
Chen, L-T.
ANNALS OF ONCOLOGY, 2017, 28
[43] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Ohtsu, A.
Tabernero, J.
Bang, Y. -J.
Fuchs, C. S.
Sun, L.
Wang, Z.
Csiki, I.
Koshiji, M.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2015, 26 : 69 - 69
[44] Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.
Al-Batran, Salah-Eddin
Shitara, Kohei
Folprecht, Gunnar
Moehler, Markus H.
Goekkurt, Eray
Ben-Aharon, Irit
Lonardi, Sara
Stein, Stacey
Hubert, Ayala
Chau, Ian
Mishaeli, Moshe
Villanueva, Luis
Kavan, Petr
Fang, Xiao
Shih, Chie-Schin
Bhagia, Pooja
Wyrwicz, Lucjan S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 247 - 247
[45] Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
Shitara, K.
Rha, S. Y.
Wyrwicz, L. S.
Oshima, T.
Karaseva, N.
Osipov, M.
Yasui, H.
Yabusaki, H.
Afanasyev, S.
Park, YK.
Al-Batran, SE.
Yoshikawa, T.
Weber, P. E. Yanez
Di Bartolomeo, M.
Lonardi, S.
Fang, X.
Shih, CS.
Bhagia, P.
Bang, YJ.
ANNALS OF ONCOLOGY, 2023, 34 : S1316 - S1316
[46] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Ohtsu, Atsushi
Kher, Uma
Lam, Baohoang
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[47] Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859.
Wyrwicz, Lucjan
Kalampoki, Vasiliki
Valderrama, Adriana
Ramakrishnan, Karthik
Young, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[48] Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Wyrwicz, L.
Oh, D.
Weber, P.
Bai, Y.
Ryu, M.
Lee, J.
Rivera, F.
Alves, G. Vasconcelos
Garrido, M.
Shiu, K.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Rha, S.
ANNALS OF ONCOLOGY, 2023, 34 : S181 - S181
[49] Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[50] Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →